TRANSFORMATION OF MYELODYSPLASTIC SYNDROME (REFRACTORY ANEMIA WITH EXCESS BLASTS) INTO ACUTE MYELOID LEUKEMIA – A CLINICAL CASE
Main Article Content
Abstract
Despite the presence in the doctor’s arsenal of tools that can determine the risk of the course of myelodysplastic syndromes and predict the volume of examination and treatment of the patient, the ability of the disease to transform into acute myeloid leukemia at lightning speed requires the medical worker to quickly make a decision on changing the treatment strategy. The presented clinical case clearly demonstrates that, despite the rapid change in therapy, the prognosis for such patients is poorly predicted.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Lindsley RC. Uncoding the genetic heterogeneity of myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2017; (1): 447-452. doi:10.1182/asheducation-2017.1.447
Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 2016; 91(1): 76-89. doi: 10.1002/ajh.24253
Dao KT. Myelodysplastic Syndromes: Updates and Nuances. Med Clin North Am. 2017; 101(2): 333-350. doi:10.1016/j.mcna.2016.09.006
Hasserjian RP. Myelodysplastic Syndrome Updated. Pathobiology. 2019; 86(1): 7-13. doi: 10.1159/000489702
Myelodysplastic syndrome in adults: Clinical recommendations. National Hematology Society, 2014. Russian (Миелодиспластический синдром у взрослых: Клин реком. Национ. гематол. общество, 2014)
Sherman AE, Motyckova G, Fega KR, et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013; 37(9): 998-1003. doi: 10.1016/j.leukres.2013.05.013
David P. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018; 8(5): 47
Fenaux P, Ades L. How we treat lower risk myelodysplastic syndromes. Blood. 2013; 121: 4280-4286
Chistyakova GN, Shabaldin AV, Belenkova OV, Moses VG. et al. A method for evaluating an allogeneic immune response in a short-term mixed culture of unrelated donor mononuclear cells. Patent for invention RU 2581925 C2, 04.20.2016. Application No. 2014126263/15 dated 06/27/2014. Russian (Чистякова Г.Н., Шабалдин А.В., Беленкова О.В., Мозес В.Г. и др. Способ оценки аллогенного иммунного ответа в кратковременной смешанной культуре мононуклеаров неродственных доноров. Патент на изобретение RU 2581925 C2, 20.04.2016. Заявка № 2014126263/15 от 27.06.2014)
Moses VG. The role of systemic lesions of connective tissue in the genesis of varicose veins of the small pelvis in adolescents. Kazan Med J. 2006; 2: 102-104. Russian (Мозес В.Г. Роль системного поражения соединительной ткани в генезе варикозного расширения вен малого таза у подростков //Казанский медицинский журнал. 2006. Т. 87, № 2. С. 102-104)
Grignano E, Jachiet V, Fenaux P, Ades L, Fain O, Mekinian A. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol. 2018; 97(11): 2015-2023. doi: 10.1007/s00277-018-3472-9
Hiwase DK, Singhal D, Strupp C, et al. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. Am J Hematol. 2017; 92(6): 508-514. doi: 10.1002/ajh.24704